In this trial, TGFB1 and IL-8 mRNA positively correlated with the immunologic responses to glioma antigens in the EVs isolated from the post-vaccine group, suggesting the potential of mRNAs carried by EVs to assess the response of vaccination therapy in glioma patients (Muller et al., 2015). Here, TGFB1 is linked to glioma.